INDIVIDUALS with drug-resistant epilepsy experience lower quality of life and face reduced employment opportunities compared to those newly diagnosed.
These were some of the findings revealed in The Florey's latest study on Purple Day for Epilepsy yesterday.
With a pilot study of 172 epilepsy patients aged 18-65, The Florey lays the groundwork for a larger initiative - the Australian Epilepsy Project.
The study also looked at seizure control and mood disorder treatment.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 24
